How No­var­tis as­sess­es a drug's prob­a­bil­i­ty of suc­cess pri­or to the piv­otal tri­al

Tran­si­tion­ing a de­vel­op­ing com­pound from ear­ly phase clin­i­cal tri­als to a piv­otal tri­al(s) can be a make-or-break de­ci­sion for a small- or medi­um-sized phar­ma. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER